Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WNT974 in Metastatic Head and Neck Squamous Cell Carcinoma
NCT02649530Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WNT974 in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Number of patients with stable disease, complete response and partial response at 4 months. Status: withdrawn.
02
Drugs
WNT974
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02649530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649530.